trastuzumab (subcutaneous and intravenous forms)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for trastuzumab (subcutaneous and intravenous forms), covering 2020-09-04 to 2020-09-04. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years [Phase 3]